NCT05088343View on ClinicalTrials.gov

Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 7, 2020

Primary Completion Date

January 16, 2021

Study Completion Date

January 16, 2021

Conditions
Healthy Subjects
Interventions
DRUG

Rosuvastatin

Single oral dose of rosuvastatin on Day 1 or co-administered with hetrombopag on Day 11.

DRUG

Hetrombopag

7.5 mg hetrombopag was administered on Day 6 to Day 11.

Trial Locations (1)

Unknown

Xueying General Ding, Shanghai

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects | Biotech Hunter | Biotech Hunter